Study guide
14.4 Safe Prescribing Principles & Antimicrobial Stewardship
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
14.4 Safe Prescribing Principles & Antimicrobial Stewardship
Key Takeaways Explain This Topic AI
Safe NHS prescribing mandates generic drug names, clear indications, complete patient and prescriber identifiers, explicit allergy documentation, and zero-tolerance for trailing zeros (write 1 mg not 1.0 mg) or ambiguous abbreviations (write 500 micrograms, units).
Renal and hepatic impairment require systematic pharmacokinetic dose adjustments: renally eliminated agents (metformin, aminoglycosides, DOACs, LMWH) risk toxic accumulation, while drugs with high first-pass clearance risk profound toxicity in cirrhosis.
Cytochrome P450 interactions govern critical patient safety: enzyme inducers (CRAP GPS) cause therapeutic failure of warfarin, DOACs, and oral contraceptives, whereas enzyme inhibitors (SICKFACES.COM) cause substrate accumulation, risking catastrophic bleeding with warfarin and rhabdomyolysis with statins.
Antimicrobial stewardship ('Start Smart - Then Focus') demands pre-treatment microbiological cultures, guideline-based empirical prescribing, and a mandatory 48–72 hour review to restrict '4C' antibiotics and prevent Clostridioides difficile colitis (treated first-line with oral vancomycin, then fidaxomicin).
Last updated: October 2026
Safe Prescribing Principles & Antimicrobial Stewardship
Prescribing in United Kingdom clinical practice is governed by professional standards established by the General Medical Council (GMC) in Good Medical Practice and the British National Formulary (BNF). Safe prescribing requires meticulous chart documentation, dosage adjustment in organ failure, identification of Cytochrome P450 interactions, pharmacovigilance under the MHRA Yellow Card scheme, and adherence to Antimicrobial Stewardship protocols.
Standards of Safe Prescribing in NHS Practice
Prescription errors represent one of the most common causes of preventable iatrogenic patient harm. Whether utilizing electronic prescribing systems (EPMA) or conventional paper inpatient medication charts (Kardex), every legal prescription must conform to standard BNF rules:
Patient Identification: Must state patient full name, date of birth, unique hospital number (and NHS number), and inpatient ward.
Mandatory Allergy Status: The allergy box must be completed prior to any drug administration. Document the specific allergen, the precise nature of the reaction (e.g., immediate anaphylaxis vs mild gastrointestinal upset), date of occurrence, and prescriber signature. If no allergies exist, prescribers must actively write 'NKDA' (No Known Drug Allergies) and sign; leaving the allergy box blank is a serious prescribing violation.
Generic Drug Naming: Drugs must be prescribed by their approved non-proprietary generic names in clear, legible capital letters (e.g., write 'PARACETAMOL', never 'Panadol').
Exceptions to Generic Rule: Biological medicines (insulins, monoclonal antibodies, biosimilars) and medications where bioavailability differences between formulations produce clinical instability (e.g., lithium carbonate , modified-release theophylline , diltiazem , tacrolimus , ciclosporin ).
Prescriber Accountability: Every prescription entry requires a clear signature, legible printed name, contact bleep or telephone number, and GMC professional registration number.
Eliminating Ambiguity: Decimal Point & Unit Rules
Ambiguous numerical notation is a primary driver of tenfold or hundredfold dosage errors:
Never Use Trailing Zeros: Write 1 mg , NEVER 1.0 mg . If the decimal point is obscured by chart folding or faint printing, '1.0 mg' will be misinterpreted and administered as 10 mg (a fatal tenfold overdose).
Always Use Leading Zeros: Write 0.5 mL , never .5 mL . If the decimal point is missed, '.5 mL' becomes 5 mL.
Prescribing in Micrograms & Nanograms: Doses under 1 milligram must be written in full in micrograms or nanograms (e.g., write 500 micrograms , NEVER 0.5 mg ; write 100 micrograms , never 0.1 mg ). Avoid ambiguous abbreviations such as 'mcg' or 'µg'.
Prescribing Units: Never abbreviate units as 'U' or 'IU' (e.g., in insulin or heparin prescriptions). A handwritten 'U' is readily misread as a zero ('0') or a '4', turning '10 U' into '100' units—causing catastrophic hypoglycaemic brain death. Always write the word 'units' in full.
- Prescribing in Organ Impairment
- 1. Renal Impairment & Haemodynamic Drug Toxicity
Renal drug elimination depends on glomerular filtration and tubular secretion. In the UK, chronic kidney disease (CKD) is staged using estimated Glomerular Filtration Rate (eGFR via the CKD-EPI equation). However, for narrow therapeutic index drugs and DOACs, the BNF and MHRA mandate calculating Creatinine Clearance (CrCl) using the Cockcroft-Gault formula : CrCl (mL/min) = ( 140 − Age ) × Weight (kg) × 1.23 [1.04 for females] Serum Creatinine (micromol/L) \text{CrCl (mL/min)} = \frac{(140 - \text{Age}) \times \text{Weight (kg)} \times 1.23\text{ [1.04 for females]}}{\text{Serum Creatinine (micromol/L)}} CrCl (mL/min) = Serum Creatinine (micromol/L) ( 140 − Age ) × Weight (kg) × 1.23 [1.04 for females]
Renally Eliminated Drugs Requiring Dose Reduction or Cessation:
Metformin: Exclusively renally cleared; accumulates in renal failure, predisposing to fatal lactic acidosis . Review and halve dose if eGFR <45 mL/min; discontinue if eGFR <30 mL/min or in acute dehydration, sepsis, or shock.
Direct Oral Anticoagulants (DOACs): Accumulate in renal impairment, increasing major haemorrhage. Dabigatran (80% renal clearance) is strictly contraindicated if CrCl <30 mL/min. Apixaban, rivaroxaban, and edoxaban require dose reduction if CrCl 15–50 mL/min and are avoided if CrCl <15 mL/min .
Low Molecular Weight Heparins (LMWH): Enoxaparin and dalteparin accumulate in severe renal failure. If CrCl <30 mL/min, reduce therapeutic dosage by 50% , monitor anti-Factor Xa levels, or convert to intravenous Unfractionated Heparin (UFH) monitored with APTT ratios.
Other High-Risk Cleared Agents: Digoxin, aminoglycosides (gentamicin), glycopeptides (vancomycin), methotrexate (severe marrow aplasia), atenolol, and lithium.
Caution
The Haemodynamic "Triple Whammy": The concurrent co-prescription of an ACE Inhibitor or ARB + a Diuretic (Loop or Thiazide) + an NSAID (e.g. Ibuprofen, Naproxen) triggers catastrophic acute kidney injury:
Diuretics induce systemic intravascular hypovolaemia and reduce renal blood flow.
NSAIDs block renal prostaglandin synthesis, which constricts the afferent arteriole , reducing blood entry into the glomerulus.
ACE inhibitors / ARBs block angiotensin II, dilating the efferent arteriole , dissipating intraglomerular capillary hydrostatic filtration pressure.
Result: Sudden collapse of intraglomerular pressure, precipitating severe ischaemic acute tubular necrosis and anuric renal failure.
2. Hepatic Impairment
The liver governs drug clearance through phase I (oxidation via Cytochrome P450) and phase II (conjugation) metabolism, alongside synthesizing plasma proteins (albumin and clotting factors).
High First-Pass Clearance Drugs: In severe cirrhosis or portosystemic shunting, systemic bioavailability of drugs that normally undergo substantial first-pass hepatic extraction rises exponentially. Agents such as morphine , propranolol , labetalol , and verapamil achieve massive plasma concentrations from standard oral doses, causing profound respiratory arrest or cardiogenic shock.
Hypoalbuminaemia & Protein Binding: Albumin synthesis falls in chronic liver disease. Highly protein-bound drugs (e.g., phenytoin , warfarin ) have a higher unbound (free, pharmacologically active) fraction, increasing toxicity despite 'normal' total serum levels.
Precipitation of Hepatic Encephalopathy: Cirrhotic patients exhibit extreme cerebral sensitivity to central nervous system depressants. Opioids , benzodiazepines , and sedating antihistamines precipitate acute hepatic encephalopathy and coma.
Fluid Retention: NSAIDs inhibit renal prostaglandins and trigger massive sodium and water retention in cirrhotic patients, exacerbating ascites, peripheral edema, and inducing hepatorenal syndrome.
Paracetamol Safety in Liver Disease: Contrary to common misconception, paracetamol remains the analgesic of choice in stable chronic liver disease; however, the maximum daily dose must be reduced to 2 g to 3 g per 24 hours (e.g., 500 mg QDS) to prevent toxic glutathione depletion.
Cytochrome P450 Drug-Drug Interactions
The hepatic microsomal Cytochrome P450 (CYP450) isoenzyme superfamily (predominantly CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2) is the primary site of oxidative drug biotransformation. Interactions occur via enzyme induction or enzyme inhibition:
1. Cytochrome P450 Enzyme Inducers
Enzyme inducers accelerate CYP gene transcription and protein synthesis, expanding metabolic capacity over 1 to 2 weeks. Substrate drugs are degraded much faster, resulting in subtherapeutic plasma concentrations and clinical treatment failure .
Inducer Mnemonic (CRAP GPS):
- C — Carbamazepine
- R — Rifampicin (most potent known inducer)
- A — Alcohol (chronic regular abuse)
- P — Phenytoin
- G — Griseofulvin
- P — Phenobarbital
- S — St John's Wort ( Hypericum perforatum , herbal remedy)
Critical Clinical Consequences of Enzyme Induction:
Warfarin: Rapid metabolic clearance -> INR drops precipitously below therapeutic range -> thromboembolic stroke / valve thrombosis .
Combined Hormonal Contraceptives: Estrogen and progestogen are cleared rapidly -> contraceptive failure and unintended pregnancy (patients on enzyme inducers must switch to an intrauterine device [IUD/IUS] or medroxyprogesterone injection [Depo-Provera]).
Antiretrovirals, DOACs, & Corticosteroids: Plasma concentrations plummet, triggering viral breakthrough, thrombosis, or Addisonian crisis.
2. Cytochrome P450 Enzyme Inhibitors
Enzyme inhibitors compete for or directly inactivate CYP catalytic sites, exerting an almost instantaneous inhibitory effect (within 24–48 hours). Substrate drugs fail to clear, leading to drug accumulation and severe clinical toxicity .
Inhibitor Mnemonic (SICKFACES.COM):
- S — Sodium valproate
- I — Isoniazid
- C — Cimetidine
- K — Ketoconazole / Fluconazole (and other azole antifungals)
- F — Fluoxetine / Fluvoxamine (SSRIs)
- A — Alcohol (acute binge drinking)
- C — Chloramphenicol
- E — Erythromycin / Clarithromycin (macrolide antibiotics)
- S — Sulfonamides / Co-trimoxazole
- C — Ciprofloxacin (fluoroquinolones)
- O — Omeprazole
- M — Metronidazole
- Grapefruit Juice (potent intestinal CYP3A4 inhibitor)
Critical Clinical Consequences of Enzyme Inhibition:
Warfarin + Macrolides / Metronidazole / Ciprofloxacin: Massive reduction in warfarin metabolism -> INR surges to >8.0 -> catastrophic spontaneous intracranial or gastrointestinal haemorrhage .
Statins (Simvastatin/Atorvastatin) + Macrolides (Clarithromycin/Erythromycin): Inhibition of CYP3A4 causes statin accumulation -> extensive muscle necrosis, myoglobinuria, and acute tubular necrosis ( severe rhabdomyolysis ). Statins must be suspended during macrolide therapy.
Theophylline + Ciprofloxacin: Toxic theophylline accumulation -> fatal cardiac arrhythmias and intractable seizures.
Other Critical Pharmacodynamic Interactions
Serotonin Syndrome: Co-administration of multiple serotonergic agents (e.g., SSRIs + MAOIs, triptans, tramadol, linezolid, St John's Wort). Overstimulation of central 5-HT₁A and 5-HT₂A receptors causes a classic triad: neuromuscular hyperactivity (spontaneous or inducible clonus, hyperreflexia, tremor), autonomic instability (hyperthermia, diaphoresis, tachycardia, labile BP), and altered mental status (agitation, delirium).
Adverse Drug Reactions & The MHRA Yellow Card Scheme
Adverse Drug Reactions (ADRs) are classified using the Rawlins and Thompson framework :
ADR Class Type Description Mechanism & Clinical Characteristics Representative Examples & Management
Type A Augmented (Dose-dependent) Predictable from known primary or secondary pharmacology. Common (>80% of all ADRs), low mortality, high morbidity. Bradycardia from beta-blockers, bleeding from warfarin, hypoglycaemia from sulfonylureas, constipation from opioids, cough from ACE inhibitors. Management: Reduce dose or withdraw drug.
Type B Bizarre (Idiosyncratic) Unpredictable from pharmacology. Independent of dose. Uncommon, high mortality, driven by immunological hypersensitivity or pharmacogenetics. Anaphylaxis from penicillin, Stevens-Johnson syndrome from allopurinol/carbamazepine, agranulocytosis from clozapine or carbimazole, malignant hyperthermia from suxamethonium. Management: Cease drug immediately; permanent avoidance; record allergy.
Type C Chronic (Dose & Time) Related to cumulative long-term dose and duration. Adrenal suppression and osteoporosis from long-term oral corticosteroids; analgesia nephropathy from chronic NSAID use.
Type D Delayed (Time-related) Becomes apparent long after drug exposure; includes teratogenesis and secondary carcinogenesis. Phocomelia from thalidomide; neural tube defects from sodium valproate; clear cell vaginal adenocarcinoma in offspring exposed to diethylstilbestrol.
Type E End of Use (Withdrawal) Occurs abruptly following drug discontinuation. Rebound tachycardia and hypertension after stopping beta-blockers; acute insomnia and tremors after benzodiazepine cessation; opioid withdrawal.
Type F Failure (Therapeutic) Unanticipated failure of drug therapy, often secondary to drug-drug interactions or counterfeit products. Contraceptive failure when taking oral contraceptives alongside rifampicin or carbamazepine.
The MHRA Yellow Card Scheme
The Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM) operate the Yellow Card Scheme for pharmacovigilance and spontaneous ADR reporting.
Black Triangle ( ▼ \blacktriangledown ▼ ) Medicines: Designates newly licensed drugs and vaccines subjected to intensive post-marketing monitoring for 2 to 5 years. Prescribers and patients must report ALL suspected adverse reactions , no matter how minor or well-recognized.
Established Drugs: Healthcare professionals should report all serious suspected adverse reactions (reactions that are fatal, life-threatening, disabling, cause congenital malformation, or require hospitalisation/prolonged bed stay), even if the reaction is already documented in the BNF.
Antimicrobial Stewardship & Clostridioides Difficile
Antimicrobial Stewardship (AMS) encompasses systematic organizational and clinical interventions designed to optimize antimicrobial selection, dosing, route, and duration, curbing the emergence of multidrug-resistant pathogens (e.g., MRSA, ESBL, CPE) and preventing secondary infections.
UKHSA Protocol: "Start Smart - Then Focus"
Start Smart (At Initial Presentation):
Take appropriate microbiological cultures (blood cultures, urine, sputum, wound swabs, CSF) prior to commencing antimicrobials , provided this does not cause life-threatening delays in severe sepsis (where antibiotics must be administered within 1 hour).
Initiate empirical therapy compliant with local evidence-based trust antimicrobial guidelines.
Document on the drug chart and in medical notes: precise clinical indication , duration/review date , dose , and route .
Then Focus (Mandatory Clinical Review at 48 to 72 Hours):
At 48–72 hours, review all antimicrobial prescriptions alongside microbiological culture and sensitivity results. Formulate one of five definitive actions :
Stop: Cease antibiotics if clinical evaluation and biomarkers (CRP, procalcitonin) indicate no bacterial infection.
Switch (IVOST): Switch from intravenous to oral therapy if the patient is improving, afebrile for 24–48 hours, and tolerating oral intake.
Change (De-escalate): Narrow the antimicrobial spectrum based on microbiological sensitivity results (e.g., switch from meropenem to oral amoxicillin).
Continue: Maintain treatment with a clear, documented stop date and subsequent review milestone.
OPAT: Refer for Outpatient Parenteral Antimicrobial Therapy.
Minimizing the "4C" Antibiotics & Clostridioides Difficile Infection
Broad-spectrum antimicrobials decimate commensal colonic microflora (especially anaerobic bacteroidetes), allowing spore-forming Clostridioides difficile to proliferate and produce enterotoxin A and cytotoxin B. Four antibiotic classes—the "4C" antibiotics —confer the highest relative risk for precipitating C. difficile colitis and must be strictly curtailed:
- C ephalosporins (e.g., ceftriaxone, cefotaxime, cefuroxime)
- C o-amoxiclav (amoxicillin-clavulanic acid)
- C lindamycin (historically highest individual risk)
- C iprofloxacin (and all fluoroquinolones: levofloxacin, moxifloxacin)
- Diagnosis & Management of C. Difficile Colitis (NICE NG199)
Clinical Presentation: Watery, foul-smelling diarrhea (≥3 unformed stools in 24 hours), lower abdominal cramping, leukocytosis, and pyrexia.
Severity Stratification:
Mild / Moderate: Normal white cell count ( WBC < 15 × 10 9 /L \text{WBC} <15 \times 10^9\text{/L} WBC < 15 × 1 0 9 /L ), normal serum creatinine (<50% rise above baseline).
Severe: WBC > 15 × 10 9 /L \text{WBC} >15 \times 10^9\text{/L} WBC > 15 × 1 0 9 /L , OR acute serum creatinine elevation (>50% above baseline), OR temperature >38.5°C, OR severe abdominal signs.
Life-Threatening: Hypotension, septic shock, paralytic ileus, toxic megacolon, or colonic perforation.
Treatment Protocol (NICE NG199 Guidelines):
First Episode (Any Severity, Not Life-Threatening): Oral vancomycin 125 mg four times daily (QDS) for 10 days is first-line; oral fidaxomicin 200 mg twice daily (BD) for 10 days is second-line if vancomycin is ineffective (NICE NG199).
Recurrence: within 12 weeks of symptom resolution, use fidaxomicin ; after 12 weeks, vancomycin or fidaxomicin. Seek specialist advice for further recurrences (for example faecal microbiota transplant).
Important Clinical Pearl: Oral vancomycin is not absorbed systemically; it acts purely intraluminally within the colonic bowel lumen. Intravenous vancomycin is completely ineffective for treating C. difficile infection because it does not penetrate into the colonic lumen. Oral metronidazole is no longer recommended first-line due to inferior cure and higher recurrence rates.
Life-Threatening / Complicated Disease: Oral vancomycin (up to 500 mg QDS via nasogastric tube if ileus) PLUS Intravenous Metronidazole 500 mg three times daily (TDS) alongside immediate emergency colorectal surgical consultation (subtotal colectomy or diverting loop ileostomy with colonic lavage).